Pillar Biosciences has launched the oncoReveal Rapid AML Panel, a research-use-only DNA next-generation sequencing panel for acute myeloid leukaemia genomic analysis. The panel enables laboratories to generate key AML genomic results more efficiently, with sample-to-library preparation completed in under 8.5 hours without batching requirements. The panel covers guideline-informed genes based on WHO/ICC 2022 and ELN 2022 recommendations, including focused hotspots like FLT3, IDH1, IDH2, KIT, KRAS, NPM1 and NRAS, plus full coding sequences of CEBPA and TP53. It is designed as a rapid first-pass tool whilst laboratories determine whether broader comprehensive genomic profiling is needed. The American Cancer Society estimates approximately 22,720 people will be diagnosed with AML in the United States in 2026. The panel is available now for research applications.

Pillar Biosciences, based in Natick, Mass., has secured $34.5M in funding, with contributions from Illumina, Soleus Capital, and existing investors. The funds will support commercial growth, biopharma partnerships, and the expansion of clinical testing kits. Illumina's investment strengthens its partnership with Pillar, enhancing NGS solutions for precision oncology. Pillar's technology aids in rapid, cost-effective genomic profiling, crucial for advancing personalized cancer therapy.

Collaboration aims to accelerate automation of rapid NGS testingNATICK, Mass., Feb. 18, 2025 /PRNewswire/ -- Pillar Biosciences, Inc., the leader in Decision Medicine™, has entered into a strategic NGS automation application development agreement and co-marketing partnership with Hamilton Company.As part of this agreement, Hamilton will develop automation scripts and supporting technical and commercial literature for selected, commercially available, research-use-only (RUO) NGS panels from Pillar Biosciences for use on Hamilton's Microlab® STAR™ Liquid Handling Systems. The first automation script for development will be for Pillar's oncoReveal® Essential MPN panel."Time, workflow complexity and overall testing costs are barriers for the broader adoption of localized NGS testing solutions," said Dan Harma, CCO of Pillar Biosciences. "Combining the speed and simplicity of our NGS products and workflow with the global scale and automation capabilities of the Hamilton liquid handling systems will help ensure more laboratories, researchers and clinicians to receive the tumor profiling results they need faster, with lower labor costs and greater efficiency.""We are thrilled to partner with Pillar Biosciences," said Michael Mouradian, Vice President of Scientific Strategy and Market Development at Hamilton. "By combining Pillar's cutting-edge NGS solutions with Hamilton's proven automation technology and global reach, we are providing customers with a more accessible and efficient solution to accelerate NGS testing."The application development and co-marketing agreement will initially cover North America, Central America, South America, New Zealand and all APAC Countries.About Pillar BiosciencesPillar Biosciences is the leader in Decision Medicine™, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar's NGS testing solutions are powered by its proprietary SLIMamp® and PiVAT® technologies, helping to localize the testing process, reduce diagnostic costs and improve access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally